Novartis India Standalone December 2021 Net Sales at Rs 98.96 crore, up 5.53% Y-o-Y
NULL11-02-2022
NOVARTIS INDIA LTD. - 500672 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Dear Sirs, Pursuant to Regulation 39 (3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that as per the information received from the Company's Registrar and Share Transfer Agent on February 10, 2022, shareholders have reported the loss of share certificates as detailed in the attachment. Request you to take the same on record as required under the provisions of the said Regulation.10-02-2022
NOVARTIS INDIA LTD. - 500672 - Board Meeting Outcome for Outcome Of The Meeting Of The Board Of Directors Of Novartis India Limited ('The Company') Held On Thursday, February 10, 2022
Dear Sir/ Madam, Kindly note that the Board of Directors of the Company has in its meeting held today i.e. on Thursday, February 10, 2022 ("said meeting"), inter alia considered and approved the Unaudited Financial Results of the Company for the quarter and nine-months ended on December 31, 2021. In terms of the applicable provisions of SEBI Listing Regulations, please find enclosed herewith: a. the Unaudited Financial Results; and b. Limited Review Report dated February 10, 2022, issued by the Statutory Auditors of the Company with respect to the Unaudited Financial Results and taken on record by the Board of Directors of the Company. The said Meeting commenced at 11:15 a.m. and concluded at 2:35 p.m. The above is for your information and the same is also available on the Company''s website i.e. www.novartis.in10-02-2022
NOVARTIS INDIA LTD. - 500672 - For The Quarter And Nine-Months Ended On December 31, 2021
Dear Sir/ Madam, Kindly note that the Board of Directors of the Company has in its meeting held today i.e. on Thursday, February 10, 2022 ("said meeting"), inter alia considered and approved the Unaudited Financial Results of the Company for the quarter and nine-months ended on December 31, 2021. In terms of the applicable provisions of SEBI Listing Regulations, please find enclosed herewith: a. the Unaudited Financial Results; and b. Limited Review Report dated February 10, 2022, issued by the Statutory Auditors of the Company with respect to the Unaudited Financial Results and taken on record by the Board of Directors of the Company. The said Meeting commenced at 11:15 a.m. and concluded at 2:35 p.m. The above is for your information and the same is also available on the Company''s website i.e. www.novartis.in10-02-2022
NOVARTIS INDIA LTD. - 500672 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that as per the information received from the Company's Registrar and Share Transfer Agent on January 26, 2022 and January 28, 2022, the shareholders have reported the loss of share certificates, as detailed in the attachment. Request you to take the same on record as required under the provisions of the said Regulation.28-01-2022
NOVARTIS INDIA LTD. - 500672 - Shareholding for the Period Ended December 31, 2021
Novartis India Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2021. For more details, kindly Click here20-01-2022
Novartis CEO sees better place' with Covid by year-end
This may be the year when the world comes to terms with the persistent reality of Covid-19 and reaches a new sense of normalcy, Novartis CEO Vas Narasimhan said18-01-2022
NOVARTIS INDIA LTD. - 500672 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39 (3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that we are issuing a duplicate share certificates to the shareholders as detailed in the attachment, as per the information received from the Company's Registrar and Share Transfer Agent on January 13, 2022. Further, we wish to inform you that as per the information received from the Company's Registrar and Share Transfer Agent on January 15, 2022, the shareholder has reported the loss of share certificate as detailed in the attachment. Request you to take the same on record as required under the provisions of the said Regulation.17-01-2022
NOVARTIS INDIA LTD. - 500672 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
In reference to the captioned subject, the certificate dated January 5, 2022, issued by the Registrar and Transfer Agent of the Company i.e. Link Intime India Private Limited, in terms of the provisions of the said Regulations, for the quarter ended December 31, 2021, is enclosed herewith for your records. This is for your information and record.13-01-2022
NOVARTIS INDIA LTD. - 500672 - Statement Of Investor Complaints For The Quarter Ended December 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- Sanjay MurdeshwarDesignation :- Managing Director / Whole Time Director13-01-2022